Genen­tech and Bio­gen roll the dice on an up­start biotech with a new siR­NA ap­proach — go­ing deep in­to the brain for tar­gets in neu­rode­gen­er­a­tion

Ata­lan­ta isn’t your av­er­age stealth biotech mak­ing a de­but. They have some his­to­ry and deals to sketch out in rough out­lines.

The found­ing ex­ecs date the silent launch all the way back to mid-2019, with the pub­li­ca­tion of a sem­i­nal study look­ing at a new siR­NA strat­e­gy for neu­rode­gen­er­a­tion. And in­stead of scout­ing for their first part­ners, the fledg­ling biotech can al­ready count 2 promi­nent play­ers as al­lies in the ex­ten­sive pre­clin­i­cal work that’s been done to es­tab­lish the plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER